» Articles » PMID: 39796536

Nutritional and Microbiota-Based Approaches in Amyotrophic Lateral Sclerosis: From Prevention to Treatment

Overview
Journal Nutrients
Date 2025 Jan 11
PMID 39796536
Authors
Affiliations
Soon will be listed here.
Abstract

Metabolic alterations, including hypermetabolism, lipid imbalances, and glucose dysregulation, are pivotal contributors to the onset and progression of Amyotrophic Lateral Sclerosis (ALS). These changes exacerbate systemic energy deficits, heighten oxidative stress, and fuel neuroinflammation. Simultaneously, gastrointestinal dysfunction and gut microbiota (GM) dysbiosis intensify disease pathology by driving immune dysregulation, compromising the intestinal barrier, and altering gut-brain axis (GBA) signaling, and lastly advancing neurodegeneration. Therapeutic and preventive strategies focused on nutrition offer promising opportunities to address these interconnected pathophysiological mechanisms. Diets enriched with antioxidants, omega-3 fatty acids, and anti-inflammatory compounds-such as the Mediterranean diet-have shown potential in reducing oxidative stress and systemic inflammation. Additionally, microbiota-targeted approaches, including probiotics, prebiotics, postbiotics, and fecal microbiota transplantation, are emerging as innovative tools to restore microbial balance, strengthen gut integrity, and optimize GBA function. This review highlights the critical need for personalized strategies integrating immunonutrition and microbiota modulation to slow ALS progression, improve quality of life, and develop preventive measures for neurodegenerative and neuroinflammatory diseases. Future research should prioritize comprehensive dietary and microbiota-based interventions to uncover their therapeutic potential and establish evidence-based guidelines for managing ALS and related disorders.

Citing Articles

The Neonatal Microbiome: Implications for Amyotrophic Lateral Sclerosis and Other Neurodegenerations.

Eisen A, Kiernan M Brain Sci. 2025; 15(2).

PMID: 40002527 PMC: 11852589. DOI: 10.3390/brainsci15020195.


Actual needs of patients with amyotrophic lateral sclerosis: a qualitative study from Wuhan, China.

Zeng L, Yang F, Xu D, Zhou J, Qiao G, Wu M BMC Palliat Care. 2025; 24(1):50.

PMID: 39987111 PMC: 11846365. DOI: 10.1186/s12904-025-01684-8.

References
1.
Kasarskis E, Tandan R . Why is nutrition vital for advancing ALS care and clinical research?. Amyotroph Lateral Scler Frontotemporal Degener. 2023; 24(5-6):359-361. DOI: 10.1080/21678421.2023.2170245. View

2.
Kaul M, Mukherjee D, Weiner H, Cox L . Gut microbiota immune cross-talk in amyotrophic lateral sclerosis. Neurotherapeutics. 2024; 21(6):e00469. PMC: 11585889. DOI: 10.1016/j.neurot.2024.e00469. View

3.
Petrov D, Mansfield C, Moussy A, Hermine O . ALS Clinical Trials Review: 20 Years of Failure. Are We Any Closer to Registering a New Treatment?. Front Aging Neurosci. 2017; 9:68. PMC: 5360725. DOI: 10.3389/fnagi.2017.00068. View

4.
Freedman D, Kuncl R, Weinstein S, Malila N, Virtamo J, Albanes D . Vitamin E serum levels and controlled supplementation and risk of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2013; 14(4):246-51. PMC: 3673294. DOI: 10.3109/21678421.2012.745570. View

5.
Gantenbein K, Kanaka-Gantenbein C . Mediterranean Diet as an Antioxidant: The Impact on Metabolic Health and Overall Wellbeing. Nutrients. 2021; 13(6). PMC: 8227318. DOI: 10.3390/nu13061951. View